Twist Bioscience (TWST) EBITDA (2017 - 2026)

Twist Bioscience (TWST) has 10 years of EBITDA data on file, last reported at -$44.1 million in Q1 2026.

• EBITDA for Q1 2026 came in at -$44.1 million, down 12.12% year-over-year; the trailing twelve-month figure through Mar 2026 was -$81.3 million (up 57.49% YoY), and the FY2025 annual result was -$77.8 million, up 62.7% from the prior year.
• EBITDA slipped to -$44.1 million in Q1 2026 per TWST's latest filing, from -$30.5 million in the prior quarter.
• Over five years, EBITDA peaked at $20.2 million in Q2 2025 and troughed at -$85.6 million in Q2 2024.
• A 5-year average of -$43.6 million and a median of -$44.1 million in 2026 frame the typical range for EBITDA.
• The sharpest annual moves came in 2022 and 2025: EBITDA plunged 62.41% in 2022, then soared 123.57% in 2025.
• A 5-year view of EBITDA shows it stood at -$43.1 million in 2022, then gained by 0.56% to -$42.8 million in 2023, then grew by 25.91% to -$31.7 million in 2024, then grew by 4.0% to -$30.5 million in 2025, then slumped by 44.79% to -$44.1 million in 2026.
• Business Quant data shows TWST's EBITDA at -$44.1 million in Q1 2026, -$30.5 million in Q4 2025, and -$26.9 million in Q3 2025.